Blanchard K T, Ball D J, Holden H E, Furst S M, Stoltz J H, Stoll R E
Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877-0368, USA.
Toxicol Pathol. 1998 Jul-Aug;26(4):541-7. doi: 10.1177/019262339802600410.
Assessment of the carcinogenic potential of chemical agents continues to rely primarily upon the chronic rodent bioassay, a resource-intensive exercise. Recent advances in transgenic technology offer a potential resource conserving approach to carcinogen detection. Incorporation of oncogenes with known roles in the development of neoplasms into the genomes of laboratory rodents may provide new models with the potential of quickly and accurately separating carcinogenic from noncarcinogenic chemicals. The insertion of the v-Ha-ras oncogene into the genome of FVB/N mice imparts the qualities of genetically initiated skin in the transgenic mouse line designated as Tg.AC. The skin of either hemizygous (animals carrying the transgene on 1 allele) or homozygous (transgene copies on both alleles) Tg.AC mice promptly responds to the application of nongenotoxic carcinogens, such as the classical tumor promoting phorbol esters, with the development of squamous papillomas. Tumor production generally begins after 8-10 applications of 2.5 micrograms/mouse (3 times/wk) of 12-O-tetradecanoylphorbol 13-acetate (TPA). Maximal tumor response is usually in evidence within 20 wk. If this transgenic mouse line is to be useful in the identification of carcinogenic chemicals, experimental protocols must be systematically optimized. Experiments were conducted to compare the relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to the dermal application of TPA and the known human leukemogen, benzene. Results revealed shipment-related variabilities in the relative responsiveness of hemizygous male and female mice to the application of the proliferative agent. Homozygous mice of both sexes were more reliable and uniform in responsiveness to both TPA and benzene. Therefore, our standard protocol for the conduct of bioassays with the Tg.AC mouse line specifies the use of homozygous males and/or females.
对化学制剂致癌潜力的评估仍然主要依赖于慢性啮齿动物生物测定法,这是一项资源密集型的工作。转基因技术的最新进展为致癌物检测提供了一种潜在的资源节约型方法。将在肿瘤发生过程中具有已知作用的癌基因整合到实验啮齿动物的基因组中,可能会提供新的模型,有潜力快速准确地将致癌化学物质与非致癌化学物质区分开来。将v-Ha-ras癌基因插入FVB/N小鼠的基因组中,赋予了在指定为Tg.AC的转基因小鼠品系中具有遗传启动皮肤的特性。半合子(在一个等位基因上携带转基因的动物)或纯合子(两个等位基因上都有转基因拷贝)Tg.AC小鼠的皮肤会迅速对非遗传毒性致癌物(如经典的肿瘤促进剂佛波酯)的应用做出反应,出现鳞状乳头状瘤。肿瘤产生通常在每只小鼠每次应用2.5微克(每周3次)的12-O-十四酰佛波醇13-乙酸酯(TPA)8-10次后开始。最大肿瘤反应通常在20周内显现。如果这种转基因小鼠品系要用于识别致癌化学物质,必须系统地优化实验方案。进行了实验以比较雄性和雌性半合子及纯合子Tg.AC小鼠对皮肤涂抹TPA和已知人类白血病致癌物苯的相对反应性。结果显示,半合子雄性和雌性小鼠对增殖剂应用的相对反应性存在与运输相关的变异性。两性的纯合子小鼠对TPA和苯的反应性更可靠且更一致。因此,我们用Tg.AC小鼠品系进行生物测定的标准方案规定使用纯合子雄性和/或雌性小鼠。